The company provides IT-enabled services and software solutions, primarily focused on healthcare revenue cycle management and medical coding automation for clients in North America and other global markets.
The company claims a moat based on AI-powered healthcare technology, but financial results show persistent consolidated losses and a negative return on equity. Average ROCE of 6.5% is below the cost of capital, indicating that any purported technological advantage fails to translate into economic profits.
Management has prioritized aggressive M&A, such as the acquisition of Aideo Technologies, funded by assuming liabilities and issuing preferred stock. This strategy has led to significant net losses and a high debt-to-equity ratio, with interest coverage remaining negative.
The company's aggressive M&A strategy, exemplified by the Aideo acquisition, proved to be a value-destructive treadmill where debt-fueled growth could not outpace mounting interest obligations. As consolidated expenses continued to outstrip revenue, the negative interest coverage eventually triggered a liquidity crisis, forcing dilutive equity raises or asset fire sales. The purported AI moat failed to manifest in the bottom line, leaving the business as a collection of loss-making subsidiaries unable to service their own liabilities.
RichFakir rates Handson Global Management (HGM) Ltd's business quality as poor — 15/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Handson Global Management (HGM) Ltd is trading about 84% above our estimate of fair value; we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Handson Global Management (HGM) Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Handson Global Management (HGM) Ltd's fair value is about ₹22 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →